Production & Manufacturing
Production & Manufacturing
Bionomics commences BNC10 manufacturing activities
Australia-based international biotechnology company Bionomics has commenced manufacturing activities for anti-cancer stem cell candidate BNC10. Lonza will manufacture BNC101 at Slough facility in the UK. Bionomics CEO and managing director Dr Deborah Rathjen said,...
Production & Manufacturing
DSM, DecImmune collaborate to develop N2 pathway blocking antibody
DSM Pharmaceutical Products has entered into collaboration with venture capital funded DecImmune Therapeutics of Cambridge, US. As per the agreement, DSM will initiate the development activities for DecImmune's lead monoclonal antibody program. DecImmune is...
Production & Manufacturing
Sunshine looking for CMOs for breast cancer drug Adva-27a manufacturing
Sunshine Biopharma has started discussions with contract manufacturing organizations (CMOs) for the production of its multidrug-resistant breast cancer drug, Adva-27a. The company is looking for 1kg of Adva-27a for the forthcoming IND-Enabling animal toxicity...
Production & Manufacturing
Qualicaps to invest $26m for Whitsett facility expansion
Pharmaceutical manufacturer Qualicaps will invest $26m to expand its facility in Whitsett, North Carolina in the US. Under the expansion plans, the firm will also add additional 100,000 ft² building space. The project will...
Production & Manufacturing
Bone Therapeutics to build new manufacturing facility in Belgium
Biopharmaceutical company Bone Therapeutics has announced that it has made a €10m investment in Skeletal Cell Therapy Support (SCTS) to build a new manufacturing facility at Gosselies Scientific Park near Brussels in Belgium. The...
Production & Manufacturing
PCT to provide development, manufacturing services to Adaptimmune
Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, has signed an agreement to provide cell product development and manufacturing services for Adaptimmune's clinical trials. Adaptimmune will make use of PCT services in the development...
Production & Manufacturing
Amgen to invest $200m in new Singapore manufacturing facility
Amgen is planning to invest $200m to construct a manufacturing facility in the Tuas Biomedical Park area of Singapore. Company intends to begin the construction of the new facility shortly to expand the monoclonal...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
